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Carlo1, MA. Pfeffer1, and BD. Levy1,2,*
1Pulmonary and Critical Care Medicine, Department of Internal Medicine, Brigham and Women’s
Hospital and Harvard Medical School, Boston, Massachusetts, USA
2Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology,
Perioperative and Pain Medicine, Brigham and Women’s Hospital and Harvard Medical School,
Boston, Massachusetts, USA
Abstract
Acute Lung Injury (ALI) is a severe illness with excess mortality and no specific therapy.
Protective actions were recently uncovered for docosahexaenoic acid -derived mediators,
including D-series resolvins. Here, we used a murine self-limited model of hydrochloric acid-
induced ALI to determine the effects of aspirin-triggered resolvin D1 (AT-RvD1) on mucosal
injury. RvD1 and its receptor ALX/FPR2 were identified in murine lung after ALI. AT-RvD1
(~0.5 – 5 μg/kg) decreased peak inflammation, including bronchoalveolar lavage fluid (BALF)
neutrophils by ~75%. Animals treated with AT-RvD1 had improved epithelial and endothelial
barrier integrity and decreased airway resistance concomitant with increased BALF epinephrine
levels. AT-RvD1 inhibited neutrophil-platelet heterotypic interactions by down-regulating both P-
selectin and its ligand CD24. AT-RvD1 also significantly decreased levels of BALF pro-
inflammatory cytokines, including IL-1β, IL-6, KC and TNF-α, and decreased NF-κB
phosphorylated p65 nuclear translocation. Together, these findings indicate that AT-RvD1
displays potent mucosal protection and promotes catabasis after ALI.
INTRODUCTION
Acute lung injury (ALI) and the acute respiratory distress syndrome (ARDS) are life-
threatening disorders that contribute significantly to critical illness1. Approximately 75,000
patients die from ARDS each year in the United States2. Respiratory failure from ALI or
ARDS is a frequent cause of admission to intensive care units, often requiring ventilatory
support. Despite advances in understanding ARDS pathophysiology, no medical
interventions have proven effective in improving the outcome of patients with ALI/
ARDS3, 4. Aspiration pneumonitis is one of the leading causes of ALI/ARDS that in most
instances is self-limited5, suggesting the existence of endogenous, host protective
mechanisms.
While the cellular events that return the injured lung to homeostasis have been described by
histopathology, there remains only a limited understanding of the molecular mechanisms
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underlying this catabatic process. Polyunsaturated fatty acids (PUFAs) appear to play
important roles in ALI and its resolution. Activation of pulmonary leukocytes leads to
increased generation of arachidonic acid-derived eicosanoids that can serve as important
mediators of inflammation, vascular leak, and tissue catabasis6–8. In contrast, omega-3 fatty
acid-based nutritional supplementation can significantly improve oxygenation and decrease
the length of stay in an intensive care unit, time on mechanical ventilation, occurrence of
new organ failure, and mortality9–11.
Airway mucosa is enriched with the omega-3 fatty acid docosahexaenoic acid (DHA)12.
Resolvin D1 (RvD1) is a DHA-derived mediator first identified in resolving peritoneal
exudates13. Aspirin acetylates cyclooxygenase-2 (COX-2) to lead to the formation of
aspirin-triggered mediators, including the 17R-epimer of RvD1 termed aspirin-triggered
RvD1 (AT-RvD1)13, 14 that decreases leukocytic infiltration in murine peritonitis to a
greater extent than RvD1 and is more resistant to catalysis than RvD114. Of interest, both
COX-2 and aspirin may have beneficial actions in ALI/ARDS15, 16. Here, in a non-lethal
model of ALI, AT-RvD1 decreased lung inflammation after mucosal injury and promoted
ALI resolution by enhancing restitution of barrier integrity, decreasing circulating
neutrophil-platelet heterotypic interactions, and regulating inflammatory mediators and NF-
κB activation.
RESULTS
RvD1 and 17-HDHA are generated after mucosal injury
To determine if endogenous DHA is converted to RvD1 after ALI, murine lungs were
obtained 12h after ALI from intratracheal HCl (0.1 N, pH 1.5) and lipids were extracted
from lung homogenates for analyses (see Methods). Both RvD1 and its biosynthetic
precursor 17(S)-hydroxy-DHA (17-HDHA) were identified by LC-MS/MS based
metabololipidomics analysis (Fig. 1a–c). At this time point, RvD1 was present in pg
quantities.
ALX/FPR2 receptors are expressed on lung epithelial cells and macrophages
RvD1 and AT-RvD1 are anti-inflammatory and pro-resolving agonists at ALX/FPR2
receptors17,18, so expression of ALX/FPR2 was determined by immunohistochemistry in
murine lung at baseline and after ALI (Fig. 1d–g). ALX/FPR2 receptors were expressed at
low levels in uninjured lungs, in particular in airway epithelial cells and alveolar
macrophages (Fig. 1d–e). As early as two hours after ALI, there was an evident increase in
mucosal epithelial cell ALX/FPR2 expression (Fig. 1f) that was further increased 12h after
ALI (Fig. 1g).
AT-RvD1 reduces leukocyte recruitment after airway mucosal injury
With both RvD1 and its receptor ALX/FPR2 present in murine lung, we determined the
impact of exogenous AT-RvD1 on inflammatory responses after ALI. Because RvD1 is
rapidly inactivated 14, its epimer AT-RvD1, which partially resists metabolic inactivation,
was chosen for study. Like RvD1, AT-RvD1 is an agonist at ALX/FPR2 receptors 18. In a
first series of experiments, AT-RvD1 or a vehicle control (0.1% ethanol (vol/vol)) were
administered intravenously 15 minutes prior to instillation of HCl (0.1 N, pH 1.5) into the
left mainstem bronchus (Fig. 2a). AT-RvD1 led to significant and dose dependent
decrements in total BALF cell numbers 12 hours after ALI (67,500 ± 15,880 total BALF
cells (AT-RvD1 10ng, n=5); 53,810 ± 7836 total BALF cells (AT-RvD1 100ng, n=10);
mean ± SEM) relative to vehicle control mice (129,800 ± 10,230 total BALF cells; mean ±
SEM; n=12, p<0.01) (Fig. 2b). In particular, AT-RvD1 decreased BALF neutrophils
(PMNs) (11,550 ± 4,841 PMNs (AT-RvD1 10ng, n=5); 8,258 ± 2,988 PMNs (AT-RvD1
Eickmeier et al. Page 2
Mucosal Immunol. Author manuscript; available in PMC 2013 September 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
100ng, n=10); mean ± SEM) relative to vehicle (36,650 ± 5,649 PMNs (n=12); mean ±
SEM, p<0.01) (Fig 2c). BALF macrophages (MACs) were also decreased with AT-RvD1
(44,470 ± 7,846 MACs; (AT-RvD1 100ng, n=10); mean ± SEM) in comparison to vehicle
(91,130 ± 10,890 MACs; mean ± SEM, n = 12, p<0.01) (Fig. 2d).
In a second series of experiments to determine its pro-resolving and potential therapeutic
properties, AT-RvD1 was given two hours after airway injury (Fig. 2e). When administered
post-injury, AT-RvD1 also mediated significant decreases in total BALF cells (87,860 ±
14,550 (100ng, n=7); 130,000 ± 7,935 (vehicle, n=6); mean ± SEM, p<0.05) (Fig. 2f) and
BALF PMNs (10,520 ± 1,404 (100ng, n=7); 33,410 ± 4,885 (vehicle, n=6); mean ± SEM,
p<0.01) (Fig. 2g). No significant changes of the numbers of BALF MACs were present
when AT-RVD1 (100ng) was given after injury (Fig. 2h).
In a third series of experiments to investigate AT-RvD1’s impact on early leukocyte
trafficking after ALI, airway inflammation was monitored by BAL two hours and six hours
after ALI. While no significant differences in the numbers of total BALF cells were
identified between AT-RvD1 dosing before (−15 min) or after (+2hr) ALI, there was a lower
amplitude and earlier decrease in airway inflammation in mice that received AT-RvD1 prior
to ALI. These changes in early BALF cell numbers were correlated with BALF MACs, as
significant numbers of BALF PMNs were not evident until twelve hours after ALI (Fig. 2i–
k).
AT-RvD1 decreases lung edema and neutrophil accumulation after ALI
ALI from HCl instillation led to increased alveolar edema and inflammation (PMNs
identified as Ly-6G+ by immunostaining) (Fig. 3a). Administration of AT-RvD1 (100 ng)
either before (Fig. 3b) or 2 hours after (Fig. 3c) intratracheal acid instillation decreased both
alveolar edema and the numbers of Ly-6G+ cells relative to control mice receiving only
vehicle.
Regulation of lung neutrophil recruitment by AT-RvD1
To investigate the PMN recruitment pattern with AT-RvD1, its influence on intravascular
and interstitial PMNs was determined (see Methods). Just prior to harvesting murine lungs
12 hours after ALI, a PMN specific Gr-1 antibody was injected intravenously to label
intravascular PMNs. After BAL, the lungs were collected, prepared for FACS and stained
with a second PMN specific antibody (NIMP-14R) (see Methods). PMNs were identified by
forward/side scatter profiles and cells that were Gr-1+NIMP-14R+ were consistent with
intravascular PMNs and cells that were Gr-1−NIMP-14R+ were consistent with interstitial
PMNs (Fig. 4a). The percent interstitial and intravascular PMNs at this time point were
decreased only slightly with AT-RvD1 (100 ng) relative to vehicle control, and these
differences did not reach statistical significance (Fig. 4b–c). Of interest, the number of
circulating PMNs (1,255 ± 108 PMNs/μl, mean ± SEM) and monocytes (468 ± 37 Monos/
μl, mean ± SEM) were markedly increased twelve hours after ALI relative to control
animals without injury (243 ± 56 PMNs/μl; 153 ± 57 Monos/μl) (n=5, p<0.05) (Fig. 4d–g).
Intravenous AT-RvD1 significantly decreased the numbers of PMNs (866 ± 59 PMNs/μl,
mean ± SEM) and Monos (240 ± 63 Monos/μl, mean ± SEM) in the peripheral blood of
acid-injured mice (n=5, p<0.05) (Fig. 4d–g).
AT-RvD1 reduces lung resistance in ALI
To investigate whether treatment with AT-RvD1 had a measurable effect on lung
mechanics, we determined lung function in mechanically-ventilated, anesthetized mice.
Because of the unilateral and mild nature of the ALI in this model, marked changes in tissue
elastance are not observed8 and no significant differences were evident with AT-RvD1
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relative to vehicle controls (Fig. 5a). Of interest, the increased lung resistance 12h after ALI
in this model was significantly reduced by AT-RvD1 (100ng) given either before (0.65 ±
0.05 cmH2O*s/ml, mean ± SEM, n= 12) or after ALI (0.56 ± 0.02 cmH2O*s/ml, mean ±
SEM, n= 6) in comparison to vehicle (0.90±0.08 cmH2O*s/ml, mean ± SEM, n= 10, p<
0.05) (Fig. 5b).
AT-RvD1 enhances restitution of barrier function after ALI
Because leakage permeability changes are integral to acute inflammation and ALI and lung
histology revealed that AT-RvD1 decreased alveolar edema (Fig. 3), the actions of AT-
RvD1 on both epithelial and endothelial barrier integrity were next determined. To measure
the effects of AT-RvD1 on the restitution of epithelial barrier function after direct mucosal
injury by HCl, fluorescently labeled dextran was instilled intratracheally and 10 minutes
later BALF and right ventricular blood were obtained for measurement of fluorescence (see
Methods). The ratio of fluorescence in serum to BALF provided an index of epithelial
permeability. 12 hours after acid instillation, epithelial permeability is increased and control
mice receiving only vehicle gave serum/BALF fluorescence ratio of 0.36 ± 0.07 (mean ±
SEM, n=5) (Fig. 5c). AT-RvD1 (100ng) significantly improved epithelial barrier disruption
12h after mucosal injury with decreased serum/BALF fluorescence ratios relative to vehicle
controls when the compound was given either before injury (0.08 ± 0.03, mean ± SEM, n=3,
p < 0.05) or two hours after injury (0.09 ± 0.02, mean ± SEM, n=5, p<0.01) (Fig. 5c). Direct
actions for the compound on epithelial barrier integrity in vitro were not identified, as AT-
RvD1 (1–100nM) did not significantly change the trans-epithelial electrical resistance of
Calu-3 human bronchial epithelial cells in culture. AT-RvD1 improved vascular
permeability changes in vivo, as the amount of Evans Blue dye that extravasated into BALF
was significantly decreased in mice receiving AT-RvD1 (100ng) either before injury (4.7 ±
0.2 μg/ml, mean ± SEM, n=3, p<0.01) or two hours after injury (4.6 ± 0.8 μg/ml, mean ±
SEM, n = 3, p<0.05) in comparison to vehicle control mice (8.5± 0.8 μg/ml, n=4) (Fig. 5d).
AT-RvD1 decreases neutrophil-platelet interactions
Vascular inflammation with heterotypic interactions between PMNs, platelets and
endothelial cells are important early events in ALI19,20. To determine if AT-RvD1 regulated
these cell-cell interactions, blood was obtained from mice given either AT-RvD1 (100ng) or
vehicle alone and analyzed by flow cytometry (Fig. 5e). PMNs were identified by their
physical properties and Ly-6G staining. PMN-platelet interactions were identified as PMNs
(Ly-6G+) that were also CD41+ (platelets), and AT-RvD1 decreased the percent
Ly-6G+CD41+ cells. P-selectin (CD62P) plays important roles in PMN-platelet interactions
in ALI19,20 and AT-RvD1 decreased the numbers of Ly-6G+CD62P+ cells (Fig. 5e).
Western blot analysis of lung tissue homogenates also revealed decreased expression of both
CD62P and its granulocyte receptor CD24 in mice receiving AT-RvD1 (Fig. 5f).
Endogenous airway epinephrine levels are enhanced by AT-RvD1
Because AT-RvD1 decreased lung resistance after ALI (Fig. 5b), BALF epinephrine levels
were next determined using a specific and sensitive ELISA (see Methods). BALF
epinephrine levels were significantly increased in mice that had received AT-RvD1 (100ng)
either before injury (201.4 ± 13.2 pg/mL, mean ± SEM) or after injury (310 ± 37.1 pg/mL,
mean ± SEM) in comparison to vehicle (146.7 ± 8.4 pg/mL, mean ± SEM, n ≥ 6, p< 0.01)
(Fig. 6a).
AT-RvD1 decreases pro-inflammatory mediator release after ALI
To determine the impact of AT-RvD1 on inflammatory mediators after ALI, BALF levels of
select cytokines, chemokines and lipid mediators were determined. BALF TGF-β was
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significantly increased when AT-RvD1 was administered two hours after ALI (Fig. 6b).
BALF levels of the counter-regulatory mediators lipoxin A4 (LXA4) and IL-10 did not
increase with AT-RvD1 relative to vehicle; however, the LXA4 and IL-10 levels were
significantly different between the two AT-RvD1 treatment strategies (Fig. 6c–d). When
AT-RvD1 was given before HCl, LXA4 and IL-10 levels decreased, but there was no
significant change in LXA4 and IL-10 levels when AT-RvD1 was given two hours after
injury (Fig. 6c–d). Several pro-inflammatory mediators were significantly decreased in AT-
RvD1 treated mice, including IL-1β, IL-6, KC and TNF-α (Fig. 6e–h). No significant
changes were observed in BALF CCL3, CXCL2, CXCL10 and LTB4 (Fig. 6i–l). In
addition, levels of 8-isoprostane, a sensitive marker of oxidative stress, are low at this time
point in this model 8, and there were no significant changes apparent with AT-RvD1 (data
not shown).
AT-RvD1 decreases NF-κB p65 translocation after ALI
Because AT-RvD1 markedly decreased several pro-inflammatory cytokines, the impact of
AT-RvD1 on NF-κB activation and the cellular targets for AT-RvD1 counter-regulatory
actions were next determined by immunohistochemistry of lung sections. NF-κB activation
and nuclear translocation was identified using a phosphorylated p65 (serine 276) antibody
(see Methods). There was an increase in NF-κB phosphoserine p65 abundance and nuclear
translocation in airway epithelial cells and lung macrophages that was evident two hours
after ALI (Fig. 7a–c) and markedly increased twelve hours after ALI (Fig. 7d). Both dosing
strategies for AT-RvD1 decreased the abundance of NF-κB phosphoserine p65 in epithelial
cells and macrophages twelve hours after HCl (Fig. 7e–f).
DISCUSSION
Alveolar edema and PMN recruitment and activation are early events in acute mucosal
inflammation and ALI/ARDS1. These cellular events are subject to regulation by lipid
mediators6,19, and here RvD1 was generated after HCl-initiated ALI. The RvD1 receptor
ALX/FPR2 is expressed on PMNs, monocytes, macrophages and airway epithelial
cells21,22,17,23. Murine ALX/FPR2 lung expression was evident in airway epithelial cells
and macrophages and its abundance markedly increased after ALI. The RvD1 epimer AT-
RvD1 displayed properties of both an anti-inflammatory and pro-resolving mediator in
decreasing the severity of HCl acid-initiated ALI. Given either before or shortly after
mucosal injury, AT-RvD1 reduced several parameters of alveolar edema 12 hours after ALI,
including by histological evidence, and measures of epithelial and endothelial permeability.
There was an increase in lung tissue resistance after intratracheal administration of HCl that
was reduced by AT-RvD1 and associated with AT-RvD1-mediated increases in endogenous
BALF epinephrine levels. In addition to these actions on mucosal tissue resident cells, AT-
RvD1 also displayed potent leukocyte-directed actions, including decreased circulating
PMNs and monocytes, vascular PMN-platelet heterotypic interactions, airway PMN
infiltration, BALF pro-inflammatory mediator levels and NF-κB p65 activation in airway
epithelial cells and macrophages. Together, these findings indicate that in lung tissue and
inflammatory cells AT-RvD1 harnessed several cell-type specific protective mechanisms to
decrease ALI severity. AT-RvD1’s regulation of vascular PMN-platelet interactions,
permeability changes and epinephrine levels emphasize the importance of vascular
inflammatory events in the pathogenesis of early ALI.
Retrospective analyses of patients with ARDS have identified aspirin as a protective
exposure that decreases ARDS morbidity and mortality16. In addition to inhibiting platelet
function, aspirin triggers the formation of specific pro-resolving mediators24, including AT-
RvD1 from DHA in inflamed murine and human tissues14. In murine models of acute
inflammation, AT-RvD1 decreases production of pro-inflammatory mediators and regulates
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leukocyte trafficking to inflammatory sites (reviewed in reference 25), including in
experimental models of arthritis and colitis26,27. Here, AT-RvD1 decreased lung PMN
infiltration and decreased inflammatory responses by tissue resident cells, including
endothelial and epithelial barrier function and levels of several pro-inflammatory mediators
in the injured lung. AT-RvD1 two hours after injury gave similar protection as a dose given
15 minutes prior to injury, indicating that AT-RvD1 could accelerate the resolution of ALI.
Neutrophil activation can cause bystander tissue damage that contributes to the pathogenesis
of ALI/ARDS28, so decreasing lung PMN accumulation and pro-inflammatory mediators
would be predicted to have synergistic benefit for tissue protection and catabasis after acid
injury. To this end, inhibition of PMN function in animal studies attenuates lung injury
induced by models of gastric acid aspiration29,30. RvD1 transduces potent anti-inflammatory
actions for PMNs. Single cell PMN assays in microfluidic chambers have uncovered direct
PMN actions for RvD1, but not the parent fatty acid DHA, to rapidly stop PMN migration
towards the chemoattractant IL-831 and RvD1 can regulate PMN lung recruitment in
response to LPS32. Here, early administration of AT-RvD1 appeared to reduce the amplitude
and duration of acid-initiated ALI and together with AT-RvD1’s regulation of NF-κB
activation suggests that the compound’s reduction in airway inflammation is secondary to
both direct actions on leukocytes and indirect actions to decrease the levels of inflammatory
cytokines. In addition, AT-RvD1’s actions on leukocytes to decrease their lung recruitment
in conjunction with regulation of vasoactive mediators likely accounts for the decrease in
alveolar edema with AT-RvD1. In this regard, at ocular mucosal surfaces, RvD1 decreases
cysteinyl leukotrienes33 that also play a pivotal role in vascular permeability in HCl-induced
ALI8.
Lipoxins (LXs) are arachidonic acid-derived mediators that display anti-inflammatory and
pro-resolving actions, including inhibition of in vivo PMN activation, cytokine release, and
angiogenesis (reviewed in reference 25). These protective actions are mediated, in part, by
the lipoxin A4 receptor ALX/FPR2 that can also serve as an anti-inflammatory receptor for
RvD1 and AT-RvD117,18,23. ALX/FPR2 receptor expression is increased in vitro after
airway epithelial injury21 and transgenic expression of human ALX/FPR2 receptors is
protective from HCl-initiated ALI15. Here, ALX/FPR2 receptor expression increased in vivo
12 hours after ALI in both airway epithelial cells and lung macrophages, and AT-RvD1
administration markedly decreased NF-κB activation in these ALX/FPR2 expressing cells.
While apoptotic PMNs are difficult to identify in this model of ALI, RvD1 in other model
systems are potent stimuli for macrophage efferocytosis during tissue catabasis17 and can
promote host catabatic responses that in conjunction with antibiotics promotes the resolution
of bacterial infection34. Of interest, BALF levels of LXA4 were significantly decreased by
AT-RvD1 administration before injury, which were significantly lower than LXA4 levels in
mice that received AT-RvD1 after injury. There are two implications of this finding. First,
AT-RvD1’s protective actions are independent of LXA4 generation and second, the early
events in host acute inflammatory responses to tissue injury are critical to endogenous
biosynthesis of LXA4. Early pro-inflammatory mediator formation is pivotal to lipid
mediator class-switching for the later generation of anti-inflammatory mediators, such as
LXA435,15. Administration of AT-RvD1 before injury dampened the early pro-inflammatory
mediator production with reductions in endogenous LXA4 generation 12 hours later.
Because AT-RvD1 resists rapid inactivation14 and promoted ALI resolution, the decrements
in LXA4 generation did not have adverse consequences on lung catabasis. This is in sharp
contrast with chemical inhibitors of early inflammatory mediator generation, such as COX-2
specific inhibitors or 5-lipoxygenase inhibition, which can be resolution “toxic” for tissue
injury or inflammation15,36.
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P-selectin (CD62P) is expressed by activated endothelial cells and platelets as a molecular
regulator of heterotypic PMN-platelet and platelet-endothelial cell interactions37. During
secondary capture, PMNs interact with circulating or endothelial adherent platelets to
augment PMN-endothelial interactions in inflamed vascular beds for PMN tissue
recruitment38 Of note, platelet depletion leads to diminished leukocyte recruitment in tissue
inflammation and ALI19. As a measure of vascular inflammation, heterotypic cell-cell
interactions between PMNs and platelets were monitored here in blood from the right
ventricle, just prior to entering the pulmonary vasculature. The peripheral blood leukocytosis
induced by ALI was decreased by AT-RvD1 and flow cytometry revealed a substantial
reduction in PMN-platelet interactions with AT-RvD1. In addition, the expression of P-
selectin (CD62P) and its PMN ligand CD24 was decreased by AT-RvD1 in lung
homogenates after ALI. Blocking P-selectin–dependent platelet-PMN interactions is highly
protective in a similar model of acid-initiated ALI19. In addition to circulating PMNs and
platelet-PMN interactions, resolvins can also decrease ADP-stimulated platelet
aggregation39. These findings suggest that AT-RvD1’s mucosal protection in ALI resulted,
in part, from its actions on PMNs that decreased PMN recruitment from bone marrow to
lung and decreased PMN-mediated disruption of lung barrier integrity by regulating PMN
interactions in the vasculature with platelets. Together, these findings indicate the presence
of unique homeostatic pathways for DHA-derived bioactive mediators inthe lung.
AT-RvD1 is a potent regulator of mucosal inflammation and can promote an array of
protective responses for lung catabasis after ALI. In addition, it is notable that the
pharmacologically active dose of AT-RvD1 administered i.v. was less than 100ng per
mouse, or ~0.005 mg/kg, providing evidence of this compound’s potent anti-inflammatory
and pro-resolving actions. Enteric feeding with DHA can markedly reduce ALI/ARDS
morbidity and mortality, in part via marked decreases in lung PMNs and inflammatory
mediators9,10. The potential for lung protection by DHA-derived mediators is also supported
by evidence from fat-1 transgenic mice that are protected from ALI40 and allergic airway
inflammation41. These transgenic mice express the Caenorhabditis elegans ω-3 desaturase
fat-1 gene and can endogenously generate ω-3 PUFAs from ω-6 PUFAs39 and resolvins41.
Moreover, AT-RvD1’s epimer RvD1 displays protective actions in an LPS model of acute
lung inflammation and injury32.
In summary, our findings have uncovered new roles for AT-RvD1 in promoting resolution
of acid-initiated experimental ALI. In this study, the DHA-derived lipid mediator AT-RvD1
decreased acid-initiated ALI by direct actions on circulating leukocytes and platelets with
lung protective effects on barrier function, PMN accumulation and pro-inflammatory
mediator generation. Expression of ALX/FPR2 receptors and AT-RvD1’s regulation of NF-
κB in lung mucosal epithelial cells and macrophages suggest important roles for these cells
in lung tissue catabasis that will serve as a focus of future studies. Together, these results
suggest a potential new therapeutic approach to the important clinical problem of ALI/
ARDS that emphasizes natural resolution signaling pathways.
METHODS
Acid-initiated acute lung injury (ALI) and treatment with AT-RVD1
All mice were maintained under specific pathogen-free conditions. All studies were
reviewed and approved by the Harvard Medical Area standing committee on animals
(protocol # 03618). As in reference 15, hydrochloric acid (0.1 N HCl, pH 1.5, 50μl,
endotoxin free; Sigma-Aldrich) was instilled selectively into the left mainstem bronchus of
anesthetized mice (FVB, male, 10–12 wk; CharlesRiver) via a 24-gauge angiocatheter
inserted intratracheally. Some mice received AT-RvD1 (7S,8R,17R-trihydroxy-4Z,9E,11E,
13Z,15E,19Z-docosa-hexaenoic acid; 10ng or 100ng) or vehicle (0.1% (vol/vol) ethanol) in
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saline by intravenous injection either 15 minutes before ALI or 2 hours after ALI was
initiated. At select time points (2, 6 and 12 hours) after acid instillation, bilateral
bronchoalveolar lavage (BAL) was performed with 2 aliquots of 1ml of PBS plus 0.6mM
EDTA.
Leukocyte recruitment after ALI
The total cell counts and leukocyte differential in BAL fluids (BALFs) were determinedas
previously described8. Briefly, total cells in BALFs were counted using a hemocytometer,
and a leukocyte differential count was performed after Wright-Giemsa staining.
To determine intravascular and interstitial PMNs, FITC-Gr-1 (Clone RB6-8C5, eBioscience,
San Diego, CA) was intravenously injected 5 minutes prior to lung harvest (similar to 19).
After BAL, the lungs were removed, dispersed and passed through a 70-μm cell strainer (as
in 42). PMNs were identified during flow cytometry by their forward/side scatter profiles
and their expression of NIMP-14R (Santa Cruz Biotechnology, Santa Cruz, CA) and Gr-1.
Isotype control antibodies were used for compensation for nonspecific binding. The FITC-
Gr-1 Ab was used to identify PMNs in the intravascular (NIMP-14R+Gr-1+) and interstitial
(NIMP-14R+Gr-1−) compartments. Flow cytometry was performed using a BD FACS Canto
II flow cytometer (Becton Dickinson, San Jose, CA) and data were analyzed using FlowJo
software (Tree Star, Ashland, OR).
Complete blood count and differential count
Murine blood was drawn from the inferior vena cava and lysed with RBC lysis buffer
(eBioscience). Leukocytes were counted with a hemocytometer and differential count was
performed after Wright-Giemsa staining. For the leukocyte differential, a minimum of 200
cells were counted per slide.
Neutrophil-platelet interactions
Whole blood was collected from mice that received either AT-RvD1 (100ng) or vehicle 2
hours after ALI. Blood was lysed using 10 volumes of red blood cell lysis buffer
(eBioscience) per manufacturer’s instructions. For flow cytometry, cells were blocked with
CD16/32 Fc block (eBioscience) and then stained with Ly6G (eBioscience), CD41
(eBioscience) or CD62P (eBioscience) for 20 minutes on ice. CD24 and P-selectin protein
abundance in lung homogenates was determined by Western blot analyses. β-actin was used
as a control. Antibodies were used in the manufacturer’s recommended concentrations (1
μg/ml) (Santa Cruz Biotechnology).
Identification of RvD1 in murine lung
FVB mouse lungs were suspended in 1.0 mL cold methanol and gently ground followed by
protein precipitation for 12 hr. Samples were next extracted by SPE column and methyl
formate fractions were taken for LC-MS/MS-based lipidomics. LC-MS/MS was performed
with an Agilent 1100 HPLC (Agilent Technologies, Santa Clara, CA) equipped with an
Agilent Eclipse Plus C-18 column (4.6 mm×50 mm×1.8 μm) paired with an ABI Sciex
Instruments 5500 QRAP linear ion trap triple quadrupole mass spectrometer (Applied
Biosystems, Foster City, CA). Instrument control and data acquisition were performed using
AnalystTM 1.5 software (Applied Biosystems). The mobile phase consisted of methanol/
water/acetic acid (55/45/0.01; v/v/v) and was ramped to 88/12/0.01 (v/v/v) after 10 min,
100/0/0.01 (v/v/v) after 18 min, and 55:45:0.01 (v/v/v) after 1 minute to wash and
equilibrate the column. Mass spectrometry analyses were carried out in negative ion mode
using multiple reaction monitoring (MRM) of established specific transitions for 17-HDHA
(m/z 343>245) and RvD1 (m/z 375>215). Identification was matching retention time and
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diagnostic ions to synthetic standards43. Quantification was performed using standard
calibration curves for each, and recoveries were calculated using deuterated internal
standard (d4-PGE2)
Histology and Immunohistochemistry
After dissection, lungs were perfusion-fixed at 20 cmH20 in IHC zinc fixative buffer (BD
Pharmingen, San Diego, CA). Tissue blocks were obtained from midsagittal slices of
lungsembedded in paraffin for staining with hematoxylin and eosin (Sigma). For Ly-6G
(1/100 dilution, BD Pharmingen) immunostaining, tissue sections were de-paraffinized and
incubated for 1 hour at room temperature with anti-mouse Ly-6G antibody to stain for
PMNs. For ALX/FPR2 (1/50 dilution, Santa Cruz Biotechnology) and phosphorylated p65
subunit of NF-κB (phospho S276, 1/50 dilution, Abcam) immunostaining, tissue sections
were incubated overnight at 4°C.
Determination of Barrier Integrity
FITC-Dextran was utilized as a marker of epithelial barrier disruption (as in reference 42
with minor modification). Briefly, FITC-Dextran (50mg/kg mouse) was given
intratracheally via a 24-gauge angiocatheter. BAL with 1ml PBS was performed 10 minutes
later with concurrent collection of blood from the right ventricle. BAL and serum were
loaded onto a microwell plate and fluorescence was determined (excitation, 490nm;
emission, 520nm). The ratio of serum to BALF fluorescence was used as an index of airway
epithelial permeability. To measure vascular permeability, Evans Blue dye was utilized as a
marker for endothelial barrier disruption (as in 8). Briefly, Evans Blue dye (40 mg/kg) was
injected via tail vein and 30 minutes later BAL was performed with 1ml PBS. Extravasation
of dye into BALFs was quantified by spectrophotometry (absorbance at 650nm).
Measurement of Lung Mechanics
For measurement of tissue elastance and lung resistance, mice were anesthetized with
pentobarbital (70 mg/kg, i.p.; Abbott Laboratories, North Chicago, IL, USA) and
mechanically ventilated with a flexiVent small animal ventilator (SCIREQ, Montreal,
Canada). Lung mechanics were determined in anesthetized, ventilated animals.
Mediator levels in BALFs
Select cytokines, chemokines and total TGF beta 1 were measured in aliquots of BALF by
cytokine bead array (Aushon Biosystems, Billerica, MA). BALF epinephrine, LTB4, 8-IP,
IL-10 and LXA4 levels were measured with specific ELISAs per manufacturer’s instructions
(Rocky Mountain Diagnostics, Colorado Springs, CO (epinephrine); Cayman Chemical,
Ann Arbor, MI (LTB4, 8-IP); eBioscience, San Diego, CA (IL-10); Neogen, Lexington, KY
(LXA4)).
Statistical analysis
Data are expressed as the mean value ± SEM unless otherwise indicated. Analysis of
variance was used to determine significance for differences between more than 2 groups.
For analyses between 2 groups, cohorts were compared by Mann-Whitney-U-test.
Significance was determined with P values ≤ 0.05. Statistics were performed using
GraphPad Prism 5 for Windows (San Diego, CA).
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Figure 1. RvD1, 17-HDHA and ALX/FPR2 receptors are present in murine lungs after ALI
Murine lung homogenates were obtained 12hr after HCl-initiated ALI. Lipids were extracted
and analyzed by LC-MS/MS. (a) MRM chromatograms (375>141 and 343>245) and
representative tandem mass spectra of (b) RvD1 and (c) 17(S)-HDHA. Insets show
structures and diagnostic fragmentation ions for each. Results are representative of n=3.
Immunohistochemical analysis for ALX/FPR2 abundance was performed with lungs
obtained (d) without injury exposed to ALX/FPR2 antibody (1/50) or (e) IgG control
antibody, and (f) 2hr and (g) 12hr after ALI. Arrowheads, epithelial cells; Arrows,
macrophages. Results are representative from n=3. Original magnification ×400
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Figure 2. AT-RvD1 reduces leukocyte recruitment after airway mucosal injury
(a) AT-RvD1 (10ng, 100ng) or vehicle alone (0.1% ethanol in 0.9%NaCl (vol/vol)) were
given intravenously 15 minutes prior to ALI. 12 hours later, BAL was performed and (b)
total cells, (c) PMNs and (d) MACs in BALFs were enumerated (see Methods). (e) In a
separate cohort, the impact of AT-RvD1 (100ng) or vehicle (0.1% ethanol in 0.9%NaCl
(vol/vol)) given 2 hours after ALI was determined on BALF (f) total cells, (g) PMNs, and
(h) MACs 12 hours after ALI was initiated. (i–k) Early leukocyte recruitment to the lung
was assessed in the presence of AT-RvD1 (100ng, iv) or vehicle (0.1% ethanol in 0.9%NaCl
(vol/vol)) given 15min before or 2hr after ALI. Values represent the mean ± SEM for n ≥ 5
mice. *, p<0.05 vs. vehicle group.
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Figure 3. AT-RvD1 decreased the lung histopathologic changes after acid-initiated ALI
Lungs were obtained 12 hours after ALI from mice that were exposed to vehicle
(0.1%ethanol in 0.9%NaCl (vol/vol), upper row (a)), AT-RvD1 (100ng) prior to ALI
(middle row (b)) or AT-RvD1 (100ng) 2 hours after acid injury (lower row (c)). Lung tissue
sections were prepared from fixed, paraffin embedded organs and stained with either
hematoxylin and eosin (H&E) (left) or Ly-6G (1/100 dilution) (right) (see Methods).
Alveolar edema (white arrows) and leukocytes (black arrows) are highlighted in
representative images (n = 3); original magnification of H&E was x200 and Ly-6G was
x400.
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Figure 4. AT-RvD1 decreased peripheral blood leukocytosis to decrease lung recruitment after
ALI
(a) Intravascular PMNs (NIMP-14R+Gr-1+) were distinguished from interstitial PMNs
(NIMP-14R+Gr-1−) by FACS in (b–c) lungs obtained 12h after ALI from mice that were
exposed to vehicle or AT-RvD1 (100ng) 2h after intratracheal acid instillation. Whole blood
was collected 12h after ALI and (d) total leukocytes (WBC), (e) PMNs (g) monocytes
(Monos) and (h) lymphocytes (Lymphs) were enumerated. Values represent the mean ±
SEM for n ≥ 3 mice. *, p<0.05 vs. control group. §, p<0.05 vs. vehicle group.
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Figure 5. Counter-regulatory actions for AT-RvD1 on lung mechanics, barrier integrity and
vascular inflammation after ALI
12h after ALI in mice exposed to AT-RvD1 (100 ng) or vehicle, lung mechanics were
determined using a flexiVent mouse ventilator, including (a) tissue elastance and (b) lung
resistance (see Methods). Values represent the mean ± SEM for n ≥ 6 mice. *, p<0.05 vs.
vehicle group. (c) Epithelial and (d) endothelial barrier integrity 12h after ALI was
determined in separate animals with intratracheal FITC-dextran and intravenous Evans blue
dye, respectively (see Methods). Values represent the mean ± SEM for n ≥ 3 mice. *, p<0.05
vs. vehicle group. (e) Cell-cell interactions between PMNs and platelets were monitored by
flow cytometry. Representative (n = 3) detection of Ly6G+CD41+ and Ly6G+CD62P+ cells
in murine blood 12h after ALI. The percentages of positive cells are indicated at the top of
the respective gates. (f) Representative (n ≥ 3) Western analysis for abundance in lung
homogenates 12h after ALI of CD62P and CD24 (see Methods).
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Figure 6. Impact of AT-RvD1 on inflammatory mediator levels after ALI
Aliquots of BALFs obtained 12h after ALI were analyzed by ELISA (a,c,d,l) or cytokine
bead array (b, e–k). Values represent the mean ± SEM for n ≥ 3 mice. *, P < 0.05 vs. vehicle
group. §, P < 0.05 vs 100ng AT-RvD1 group 15min before ALI.
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Figure 7. AT-RvD1 decreased ALI-induced NF-κB p65 activation and nuclear translocation in
murine lung
Immunohistochemical analysis to detect NF-κB localization was performed by staining lung
tissue (a) without injury using NF-κB phosphorylated p65 antibody (phospho S276, 1/50) or
(b) IgG control antibody and (c) 2h after ALI. Lungs were also obtained 12h after ALI from
mice exposed to (d) vehicle or (e,f) AT-RvD1 (100 ng). Insets, higher magnification to show
nuclear staining. Arrowheads, epithelial cells; Arrows, macrophages. Results are
representative from n=3. Original magnification ×400.
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